| [1] |
Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer[J]. Semin Oncol, 2020, 47(5): 259-269. DOI: 10.1053/j.seminoncol.2020.07.008.
pmid: 32896428
|
| [2] |
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J]. N Engl J Med, 2011, 365(14): 1273-1283. DOI: 10.1056/NEJMoa0910383.
|
| [3] |
Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the north central cancer treatment group N9831 clinical trials[J]. J Clin Oncol, 2010, 28(21): 3416-3421. DOI: 10.1200/JCO.2009.23.6950.
pmid: 20530275
|
| [4] |
Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33): 3744-3752. DOI: 10.1200/JCO.2014.55.5730.
pmid: 25332249
|
| [5] |
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet, 2017, 389(10075): 1195-1205. DOI: 10.1016/S0140-6736(16)32616-2.
pmid: 28215665
|
| [6] |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792. DOI: 10.1056/NEJM200103153441101.
|
| [7] |
Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-4274. DOI: 10.1200/JCO.2005.04.173.
|
| [8] |
Chen X, Wang J, Fan Y, et al. Primary trastuzumab resistance after (Neo) adjuvant trastuzumab-containing treatment for patients with HER2-positive breast cancer in real-world practice[J]. Clin Breast Cancer, 2021, 21(3): 191-198. DOI: 10.1016/j.clbc.2020.09.003.
|
| [9] |
韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2阳性乳腺癌的靶向治疗研究进展[J]. 中华普通外科学文献(电子版), 2021, 15(6): 453-458. DOI: 10.3877/cma.j.issn.1674-0793.2021.06.013.
|
| [10] |
边莉, 徐兵河, 邸立军, 等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J]. 中华医学杂志, 2020, 100(30): 2351-2357. DOI: 10.3760/cma.j.cn112137-20200116-00105.
|
| [11] |
Tao W, Zhang P, Di L, et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study[J]. Transl Breast Cancer Res, 2022, 3: 15. DOI: 10.21037/tbcr-21-42.
|
| [12] |
Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲ randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study[J]. J Clin Oncol, 2011, 29(3): 264-271. DOI: 10.1200/JCO.2010.30.8213.
pmid: 21149659
|
| [13] |
Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3): 351-360. DOI: 10.1016/S1470-2045(20)30702-6.
pmid: 33581774
|
)
